Medical Description
Gastro Resistant tablets for the relief of heartburn. For the treatment of dyspepsia, esophagitis, gastroesophageal reflux disease, treatment and secondary prevention of peptic ulcer disease.
Indication & Usage
-Maalox Control Tablets for the short-term treatment of reflux symptoms (e.g., heartburn, acid regurgitation) in adults.
-Dosage & method of use:
The recommended dose is 20 mg pantoprazole (one tablet) per day. It might be necessary to take the tablets for 2 – 3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor.
Active Ingredients
Pantoprazole
Dosage & Administration
-Tablets should not be chewed or crushed and should be swallowed whole with liquid before a meal.
-If administering twice daily, first dose should be administered before breakfast and the second dose before dinner.
Side Effects
Edema , facial edema , thrombophlebitis, Pruritus , skin photosensitivity , skin rash , urticaria, Increased serum triglycerides, abdominal pain , constipation , diarrhea , flatulence , nausea , vomiting , xerostomia ,Leukopenia , thrombocytopenia, hepatitis , increased liver enzymes, hypersensitivity reaction, depression , dizziness , vertigo arthralgia, increased creatine phosphokinase in blood specimen , myalgia, blurred vision, fever.
Safety Advice
-The treatment should not exceed 4 weeks without consulting a doctor.
-Not recommended for use in children and adolescents below 18 years of age.
-Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B12 and subsequent vitamin B12 deficiency
-Incase of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.
Storage
Store of Temperature not exceeding 30 °C.
Drug Interactions
-Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives.
-Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime
-Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime
-Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.
-Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole.
-Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.
-Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals
Pregnancy & Lactation
-Ask your physician before taking any medication during pregnancy or lactation.
-Based on available data, PPIs may be used when clinically indicated.
-The relative infant dose (RID) of pantoprazole was determined to be 0.14% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 40 mg/day.In general, breastfeeding is considered acceptable when the RID is <10%